Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01177202 · ClinicalTrials.gov registry record · Phase 1

Study of the Safety and Immunogenicity of H1N1 Vaccine

A Phase 1 study, sponsored by Fraunhofer, Center for Molecular Biotechnology.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target

NCT01177202 is a Phase 1 study that has completed, run by Fraunhofer, Center for Molecular Biotechnology. The registered enrollment target is 80 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01177202, a Phase 1 study, has completed, sponsored by Fraunhofer, Center for Molecular Biotechnology.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target

Study Summary

The Purpose Of This Study Is To Assess The Safety, Immunogenicity, And Tolerability Of A H1N1 Vaccine In Healthy Adults

Interventions

  • BIOLOGICAL HAC1 Vaccine

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2010-09
Est. Completion 2012-10
Phase Phase 1

What the Registry Record Tells You About NCT01177202

The ClinicalTrials.gov registry entry for NCT01177202 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fraunhofer, Center for Molecular Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which HAC1 Vaccine is the first listed.

NCT01177202 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01177202 about?

NCT01177202 is a clinical study titled "Study of the Safety and Immunogenicity of H1N1 Vaccine". The Purpose Of This Study Is To Assess The Safety, Immunogenicity, And Tolerability Of A H1N1 Vaccine In Healthy Adults

What is the current status of trial NCT01177202?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2010-09. Estimated completion is 2012-10.

What interventions are being tested in trial NCT01177202?

The interventions under investigation include: HAC1 Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT01177202?

This trial is sponsored by Fraunhofer, Center for Molecular Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.